Close Menu

NEW YORK – NeoGenomics on Tuesday reported a 20 percent year-over-year increase in its third quarter revenues, primarily due to higher testing volume.

For the three months ended Sept. 30, total revenues reached $125.4 million, up from $104.7 million in Q3 2019, but short of the consensus analysts' estimate of $126.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.